It has also set its sights on geographic expansion in new territories like Poland, Italy, Spain, Czech Republic, Portugal and France, as the generic drug market in these countries is relatively small.

[12] In 2017, Aurobindo Pharma inked a pact to acquire Portugal's Generis Farmaceutica SA from Magnum Capital Partners for a consideration of €135 million.

As part of the proposed sale, Apotex will enter into a transitional manufacturing and supply arrangement with Aurobindo to support the ongoing growth plans of these businesses.

[16] In December 2016, 20 American attorneys general filed a civil complaint accusing Aurobindo Pharma of a coordinated scheme to artificially maintain high prices for a generic antibiotic and diabetes drug.

The complaint alleged price collusion schemes between six pharmaceutical firms including informal gatherings, telephone calls, and text messages.

In November 2019, Aurobindo Pharma USA recalled ranitidine tablets, capsules, and syrup due to the detection of unacceptable levels of N-nitrosodimethylamine (NDMA).